Company Profile
Senseonics Stock Price, News & Analysis
- Ticker:
- SENS
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.15 USD (-0.58%)
Close
Last updated: August 6, 2026
359M USD
Market cap
Why the stock is moving
The latest monitored company update is “Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial Results.” The corresponding closing-price reaction is not yet available.
Company overview
Implantable Glucose Monitoring
Senseonics develops long-term implantable continuous glucose-monitoring systems for people with diabetes. Its technology places a fluorescence-based sensor under the skin rather than relying on frequently replaced transcutaneous sensors.
Eversense 365
Eversense 365 is designed to provide up to one year of continuous glucose data from a single implanted sensor. A removable external transmitter powers the sensor and sends readings and alerts to a mobile application. Senseonics manufactures the system and now directly manages U.S. commercialization. The company is also transitioning more international sales and marketing activities in-house.
Future catalysts
Senseonics’s catalysts are Eversense 365 adoption and distribution growth in continuous glucose monitoring. The stock will care most about whether the installed base keeps widening.
Recent news
- 01
Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial Results
Source: Senseonics
- 02
- 03
- 04
- 05
Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results
Source: Senseonics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Senseonics (SENS)?
Senseonics (SENS) most recently closed at 5.15 USD, a -0.58% move versus the previous session.
What is the market cap of Senseonics (SENS)?
Senseonics currently has a market capitalization of 359M USD on BioPharmSignal.
What does Senseonics do?
Implantable Glucose Monitoring Senseonics develops long-term implantable continuous glucose-monitoring systems for people with diabetes. Its technology places a fluorescence-based sensor under the skin rather than relying on frequently replaced transcutaneous sensors. Eversense 365 Eversense 365 is designed to provide up to one year of continuous glucose...
On which exchange is SENS stock listed?
Senseonics (SENS) is associated with NYSE, United States, Biopharma.
What is Implantable?
Implantable Glucose Monitoring Senseonics develops long-term implantable continuous glucose-monitoring systems for people with diabetes.
Which conditions is Senseonics targeting with Implantable?
Senseonics is associated with diabetes based on its company overview and current catalyst commentary.
How does Senseonics describe recent progress with Implantable?
Senseonics’s catalysts are Eversense 365 adoption and distribution growth in continuous glucose monitoring. The stock will care most about whether the installed base keeps widening.
What is Glucose?
Implantable Glucose Monitoring Senseonics develops long-term implantable continuous glucose-monitoring systems for people with diabetes.